Обзорная статья

Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer

Zibai LyuDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USASiyue NiuDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USAYing FangDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USAYuning ChenDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USAYan-Ruide LiDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USA. [email protected]Lili YangDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, USA. [email protected]

2025en

ABI

Аннотация

Allogeneic cell-based immunotherapies, particularly CAR-T cell therapy, represent a significant advancement in cancer treatment, offering scalable and consistent alternatives to autologous therapies. However, their widespread use is limited by the risk of graft-versus-host disease (GvHD). This review provides a comprehensive overview of GvHD in the context of allogeneic cell-based cancer immunotherapy and evaluates current strategies to mitigate its effects. Key strategies include genetic engineering approaches such as T cell receptor (TCR) knockout (KO) and T cell receptor alpha constant (TRAC) CAR knock-in. Alternative immune cell types like natural killer (NK) cells and natural killer T (NKT) cells offer potential solutions due to their lower alloreactivity. Additionally, stem cell technology, utilizing induced pluripotent stem cells (iPSCs), enables standardized and scalable production of engineered CAR-T cells. Clinical trials evaluating these strategies, such as UCART19 and CTX110, demonstrate promising results in preventing GvHD while maintaining anti-tumor efficacy. The review also addresses manufacturing considerations for allogeneic cell products and the challenges in translating preclinical findings into clinical success. By addressing these challenges, allogeneic cell-based immunotherapy continues to advance, paving the way for more accessible, scalable, and effective cancer treatments.

Перевод пока недоступен

Идентификаторы

DOI: 10.1186/s40164-025-00654-3

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar